Company intelligence / Profile preview

Xenetic Biosciences, Inc.

Framingham, Massachusetts, United Statesxeneticbio.com ↗

Ownership: Public · XBIO
Development stage: Other

Overview

Xenetic has reported positive preclinical data showing that its DNase I intervention can enhance CAR-T cell therapy efficacy in solid tumors by targeting NETs. The company’s systemic DNase program and XCART™ CAR T program are advancing toward clinical development. No late-stage or commercial results have been reported as of May 2025[7].

Therapeutic areas: Oncology
Modalities: Enzyme therapy (systemic DNase)Cell therapy (CAR T)Drug delivery platform (PolyXen®)
Industry: Biotech

Drug pipeline

4 assets

cridanimod

3 more assets in the full pipeline.

Partnerships

The Scripps Research Institute – collaboration on systemic DNase and CAR-T programs[5]VolitionRx Limited – collaboration on NET-targeted adoptive cell therapies for cancer[8]Takeda Pharmaceuticals Co. Ltd. – exclusive license agreement for PolyXen® technology in coagulation disorders with royalty payments to Xenetic[6][8]

Financials

Market cap: $4.4M
Total revenue: $3M
Enterprise value: $-2.1M

Beyond the preview

Go deeper on Xenetic Biosciences, Inc..

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Xenetic Biosciences, Inc..